Trials / Completed
CompletedNCT00487682
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 403 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP2151 | oral |
| DRUG | Valacyclovir hydrochloride | oral |
Timeline
- Start date
- 2007-11-13
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2007-06-18
- Last updated
- 2018-11-23
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00487682. Inclusion in this directory is not an endorsement.